VolitionRx Limited Schedules Fourth Quarter and Full Year 2016 Earnings Conference Call and Business Update

Conference call to take place Friday, March 10, 2017 at 8:30am E.T.

NAMUR, Belgium, March 6, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX) today announced it will host a conference call on Friday, March 10th, 2017 at 8:30am E.T. (Eastern U.S time) to discuss its financial results for the fourth quarter and full year 2016, in conjunction with the filing of its annual report on Form 10-K for the fourth quarter and full year ended December 31, 2016.

Cameron Reynolds, Chief Executive Officer of Volition, will host the call and provide an update on recent developments, including details of the ongoing clinical trials and commercial progress of the Company's Nu.Q™ Colorectal Cancer blood-based diagnostic platform.  To participate in the call, please dial 1-877-407-0789 (toll-free) in the U.S. and Canada, 0 800 756 3429 (toll-free) in the U.K., and 1-201-689-8562 (toll) internationally. The conference ID number is 13656572.


VolitionRx Limited Q4 & Full Year 2016 Earnings and Business Update Conference Call


Friday, March 10, 2017


8:30 am (Eastern Time)

U.S. & Canada Dial-in:

U.K. Dial-in:

1-877-407-0789 (toll free)

0 800 756 3429 (toll free)

International Dial-in:

1-201-689-8562 (toll)

Conference ID:


A live audio webcast of the conference call will also be available on the investor relations page of Volition's corporate website at http://ir.volitionrx.com. In addition, a telephone replay of the call will be available until March 24th, 2017. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the U.S. and Canada and 1-412-317-6671 (toll) internationally. Please use replay pin number 13656572.

About Volition

Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid -- an indication that disease is present.

As cancer screening programs become more and more widespread, our products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life.

Volition's research and development activities are currently centered in Belgium, with additional offices in London, New York, and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.

For more information about Volition, visit Volition's website (http://www.volitionrx.com) or connect with us via:

Twitter: https://twitter.com/volitionrx 
LinkedIn: https://www.linkedin.com/company/volitionrx 
Facebook: https://www.facebook.com/VolitionRx/ 
YouTube: https://www.youtube.com/user/VolitionRx

The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document.  The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.

Media / Investor Contacts

Louise Day, Volition


+44 (0)7557 774620

Scott Powell, Volition


+1 (646) 650 1351

Tirth Patel, Edison Advisors


+1 (646) 653 7035

Rachel Carroll, Edison Advisors


+44 (0)20 3077 5711

Sarah Roberts, Vane Percy & Roberts


+44 (0)1737 821 890

Nucleosomics®, NuQ®, Nu.QTM and HyperGenomics® and and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/volitionrx-limited-schedules-fourth-quarter-and-full-year-2016-earnings-conference-call-and-business-update-300418629.html

SOURCE VolitionRx Ltd